BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TXA127: Phase II started

Tarix began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate daily 300 µg/kg subcutaneous TXA127 for up to 28 days following autologous peripheral blood stem cell transplant in...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >